...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Vaccination with genetically engineered allergens prevents progression of allergic disease
【24h】

Vaccination with genetically engineered allergens prevents progression of allergic disease

机译：基因工程过敏原的疫苗接种可预防过敏性疾病的进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IgE-mediated allergy affects >25% of the population in industrialized countries. Repeated contact with the disease-eliciting allergens induces rises of allergen-specific IgE Abs and progression of the disease to more severe manifestations. Our study uses a type of vaccine that is based on genetically modified allergen derivatives to treat allergic patients. We developed hypoallergenic derivatives of the major birch pollen allergen. Bet v 1, by genetic engineering and vaccinated birch pollen-allergic patients (n = 124) in a double-blind, placebo-controlled study. Active treatment induced protective IgG Abs that inhibited allergen-induced release of inflammatory mediators. We also observed a reduction of cutaneous sensitivity as well as an improvement of symptoms in actively treated patients. Most important, rises of allergen-specific IgE induced by seasonal birch pollen exposure were significantly reduced in vaccinated patients. Vaccination with genetically engineered allergen derivatives is a therapy for allergy that not only ameliorates allergic reactions but also reduces the IgE production underlying the disease.
机译：在工业化国家，IgE介导的过敏影响超过25％的人口。反复接触引起疾病的过敏原会引起过敏原特异性IgE Abs升高，并使疾病进展为更严重的表现。我们的研究使用一种基于转基因过敏原衍生物的疫苗来治疗过敏性患者。我们开发了主要的桦树花粉过敏原的低变应原性衍生物。在一项双盲，安慰剂对照研究中，由基因工程和接种桦树花粉过敏的患者（n = 124）进行的Bet v 1研究。积极治疗可诱导保护性IgG Abs抑制过敏原诱导的炎症介质释放。我们还观察到积极治疗的患者皮肤敏感性降低，症状改善。最重要的是，在接种疫苗的患者中，季节性桦木花粉暴露引起的变应原特异性IgE升高明显降低。用基因工程变应原衍生物进行疫苗接种是一种变态反应疗法，不仅可以改善变态反应，还可以减少该疾病的IgE产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号